GlassScriptPhysician profile
Jeffrey P Corbett
NPI 1376751016
$2,496.68
in general payments reported to CMS, 2019-2025
25 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $130 · 2024: $960 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $333.11 | 2024-2025 | |
| Lilly USA, LLC | $256.67 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $222.42 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $211.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $199.09 | 2024-2025 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $166.89 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $154.17 | 2024-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Abiomed | $139.76 | 2022-2025 | Impella |
| Collegium Pharmaceutical, INC. | $123.36 | 2024-2025 | Belbuca, Xtampza, Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.50 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $98.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $88.90 | 2022 | |
| Glaxosmithkline, LLC. | $71.53 | 2024-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Sanofi-Aventis U.S. LLC | $46.53 | 2024 | |
| Janssen Pharmaceuticals, INC | $35.03 | 2024 | Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.14 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $30.88 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.17 | 2025 | Caplyta |
| Biogen, INC. | $28.59 | 2025 | Zurzuvae |
| Phathom Pharmaceuticals, INC. | $24.65 | 2025 | Voquezna |
| Acadia Pharmaceuticals INC | $23.82 | 2025 | Nuplazid |
| Abbott Laboratories | $21.55 | 2024 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $21.29 | 2025 | |
| Viiv Healthcare Company | $19.05 | 2024 | Apretude |
| Edwards Lifesciences Corporation | $15.35 | 2025 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.